Search PubMed⌕ Search

Biomedical subjects

A Goudeau

Publications and source records attributed to A Goudeau.

At least 145 records · Page 8Linked to original sources
PubMed1982

Immune response in neonates to hepatitis B vaccine.

Three injections of alum hepatitis B vaccine (HB vaccine) were given to 26 Senegalese infants, the first when they were less than 1 month old, and the second and third after 1-month intervals. 94.7% of the neonates whose serum was negative for hepatitis B surface antigen and antibodies against the surface antigen (anti-HBs) showed a specific anti-HBs response. Anti-HBs titres in the neonates were similar to those previously obtained in Senegalese children aged aged 1-24 months. HB vaccine was without sid-effects and was immunogenic in the neonates, irrespective of the hepatitis-B-marker status of the mothers or the children.

Antibodies, Viral↗
PubMed1982

[Hepatitis B virus and hepatoma: evidence for a cytoplasmic tumor antigen in transformed hepatocytes].

A tumoural antigen (HBV/T Ag) has been found in the cytoplasm of the human hepatoma cell line PLC/PRF/5 by indirect immunofluorescence and immunoperoxidase assays using anti-sera from Senegalese patients with primary hepatocellular carcinoma. The same antigen was detected in PHC tissues. According to the data obtained with serum and tissue controls the HBV/T Ag-anti-HBV/T system seems associated with transformation of hepatocytes by hepatitis B virus.

Antigens, Viral↗
PubMed1982

Immunogenicity in chimpanzees of experimental hepatitis B vaccines prepared from intact hepatitis B virus, purified polypeptides, or polypeptide micelles.

The immunogenicity of three experimental hepatitis B vaccines was evaluated in chimpanzees. Although no antibody to hepatitis B surface antigen (anti-HBs) was detected in two chimpanzees that received an aqueous polypeptide vaccine subcutaneously, a strong anti-HBs response was observed two and ten weeks, respectively, following challenge with hepatitis B virus. Inoculation of two additional chimpanzees with a micellar preparation of these polypeptides by the intravenous route resulted in anti-HBs production in one of the chimpanzees. Two chimpanzees inoculated subcutaneously with an aqueous vaccine of formalin-inactivated intact hepatitis B virus developed anti-HBs in low titers, but the development of antibody to the hepatitis B core antigen following challenge inoculations suggested that subclinical HBV infections may have occurred despite prior vaccination.

Animals↗
PubMed1982

Large-scale isolation of the two major polypeptides of the hepatitis B surface antigen (HBsAg) by gel filtration in 6 M guanidinium chloride.

Purified hepatitis B surface antigen (HBsAg) of subtype ay was solubilized in guanidinium chloride and submitted to chromatography on Sepharose 4B in the presence of guanidinium chloride. The polypeptides P1 (Mr = 24,000) and P2 (Mr = 29,000) were eluted in the same fraction with a minor contaminant (Mr = 40,000). Large amounts of these two polypeptides were obtained in a single step. This technique which constitutes a method for large-scale purification of the P1 and P2 polypeptides should permit more complete characterization of the P1 and P2 polypeptides and of their antigenic determinants.

Chromatography, Gel↗
PubMed1982

[Vaccination against hepatitis B in a hemodialysis unit. A 4-year follow up (author's transl)].

From February 1976 to January 1980, 123 staff members and 84 hemodialysis patients were immunized against hepatitis B in an adult hemodialysis unit. The vaccine was prepared by purification of HBs Ag from human sera and was formalin inactivated. Vaccines were tested for seric markers of HB virus (HBs Ag, anti-HBs, anti-HBc) and serum transaminases (ALT, AST) before immunization and every month during the follow up. Tests for markers of auto-immunity were performed. The vaccinees were followed from 4 to 48 months. No evidence of long-lasting reactions to the HB vaccine or auto-immunity was observed. 91% of the staff members sero-converted for anti-HBs; none of them showed clinical, biologic or serologic signs of active HB infection; 62% of the hemodialysis patients sero-converted for anti-HBs; none of them became HBs Ag chronic carrier. These results were obtained despite the fact that the prevalence of HBs Ag chronic carriers was 32.7% when the study began. Active immunization proved to be a safer and efficient method to prevent HB infection in a hemodialysis unit.

Autoantibodies↗
PubMed1982

Vaccine against hepatitis B in children: prevention of hepatitis in a pediatric hemodialysis unit.

In a pediatric hemodialysis unit, 10 children (aged 1 to 14 years) with chronic renal failure were immunized against hepatitis B infection (HB) by means of a vaccine. The vaccine was prepared by purification of Hepatitis B surface antigen (HGs Ag) from human sera and was formalin inactivated. Seven children were undergoing periodic hemodialysis and three were still managed with conservative treatment. There HBs Ag chronic carriers children were also dialysed in the unit and therefore represented a permanent high risk of HB for the whole unit. All the vaccinated children sero-converted for antibody to HBs Ag (anti-HBs) after vaccination. A follow-up from 16 to 33 months did not evidence clinical, biological and serological sign of hepatitis B in the vaccinated children. Presence of anti-HGs and absence of appearance of hepatitis B following immunization suggest that hepatitis B vaccine has represented for these children an effective means of prevention against hepatitis B infection.

Adolescent↗
PubMed1981

Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal).

Three doses of inactivated hepatitis B vaccine were given at one-month intervals to Senegalese children aged less than two years. A control group received diphtheria/tetanus/polio vaccine. Of those HB vaccine recipients who were seronegative before immunisation, 94.5% had a specific anti-HBs response. Anti-HBs of maternal origin did not interfere with the active immunisation. HB vaccine was without ill-effects, irrespective of hepatitis B marker status before immunisation. After twelve months' follow-up, the incidence of the HBsAg carrier state was reduced by 85% in susceptible children (p less than 0.0001).

Age Factors↗
PubMed1981

Epidemiological and serological study of hepatitis A virus outbreaks in France: a comparison between immunoadherence and radioimmunoassay.

An epidemiological study and the simultaneous evaluation of anti-HAV antibody using radio immunoassay (RIA) and immunoadherence hemagglutination assay (IAHA) was performed during three hepatitis A epidemics in the Tours area (France). Fifty-seven sera from 35 subjects with viral hepatitis type A and 16 sera from nine children who did not develop any clinical signs of hepatitis were studied. The more explosive epidemic occurred in an institution for mentally retarded children (attack rate 68%). The two major outbreaks observed were due to the introduction of the institutions of individuals infected with hepatitis A virus. Two out of three of the index cases had a seafood dinner three to four weeks before onset of jaundice. Sera taken one week after jaundice were always found to be anti-HAV positive by both RIA and IAHA, and sera taken more than three days before the appearance of jaundice were negative by both methods. Sera taken at the peak of the transaminase elevation were anti-HAV positive by RIA but only one out of two were positive by IAHA. The anti-HAV titre by RIA increased from the time of the appearance of jaundice and the highest titres, over 1/20000 were seen only after several months. Observations of subjects in close contact with patients who seroconverted without any manifestation of hepatitis, confirmed the existence of clinically mute infections.

Adult↗